Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 16.63 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: carmellose calcium; hyprolose; lactose monohydrate; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea or in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

torrent pharmaceuticals limited - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n), pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s) - metformin hydrochloride 500 mg - pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate [see clinical studies (14)] . important limitations of use pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin.  pioglitazone and metformin hydrochloride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.5)] . - initiation in patients with established nyha class iii or iv heart failure [see boxed warning] . - severe renal impairment (egfr below 30 ml/min/1.73 m 2 [see warnings and precautions (5.2)]. - use in patients with known hypersensitivity to pioglitazone, metformin, or any other component of pioglitazone and metformin hy

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pioglitazone hydrochloride, quantity: 16.53 mg (equivalent: pioglitazone, qty 15 mg) - tablet, uncoated - excipient ingredients: polysorbate 80; hypromellose; colloidal anhydrous silica; lactose monohydrate; croscarmellose sodium; magnesium stearate - vexazone is indicated for the treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pioglitazone hydrochloride, quantity: 33.06 mg (equivalent: pioglitazone, qty 30 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; hypromellose; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; polysorbate 80 - vexazone is indicated for the treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pioglitazone hydrochloride, quantity: 49.59 mg (equivalent: pioglitazone, qty 45 mg) - tablet, uncoated - excipient ingredients: hypromellose; colloidal anhydrous silica; croscarmellose sodium; lactose monohydrate; polysorbate 80; magnesium stearate - vexazone is indicated for the treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pioglitazone hydrochloride, quantity: 49.61 mg (equivalent: pioglitazone, qty 45 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control, in combination with metformin or sulfonylurea in combination with insulin; as triple therapy to improve glycaemic control, in combination with metformin and sulfonylurea.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pioglitazone hydrochloride, quantity: 33.07 mg (equivalent: pioglitazone, qty 30 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control, in combination with metformin or sulfonylurea in combination with insulin; as triple therapy to improve glycaemic control, in combination with metformin and sulfonylurea.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pioglitazone hydrochloride, quantity: 16.54 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control, in combination with metformin or sulfonylurea in combination with insulin; as triple therapy to improve glycaemic control, in combination with metformin and sulfonylurea.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

american health packaging - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s) - pioglitazone 15 mg

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - pioglitazone hydrochloride 16.54mg equivalent to 15 mg pioglitazone - tablet - 15 mg - active: pioglitazone hydrochloride 16.54mg equivalent to 15 mg pioglitazone excipient: carmellose calcium hyprolose lactose monohydrate magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet. effective as a single agent and may also be used in combination with sulfonylureas, metformin, or insulin when diet plus the single agent does not result in adequate glycaemic control.